SI3172227T1 - Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni - Google Patents
Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezniInfo
- Publication number
- SI3172227T1 SI3172227T1 SI201530968T SI201530968T SI3172227T1 SI 3172227 T1 SI3172227 T1 SI 3172227T1 SI 201530968 T SI201530968 T SI 201530968T SI 201530968 T SI201530968 T SI 201530968T SI 3172227 T1 SI3172227 T1 SI 3172227T1
- Authority
- SI
- Slovenia
- Prior art keywords
- molecules
- cells
- treatment
- autoimmune diseases
- selectively activate
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461999241P | 2014-07-21 | 2014-07-21 | |
| EP15824955.7A EP3172227B9 (en) | 2014-07-21 | 2015-07-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PCT/US2015/041177 WO2016014428A2 (en) | 2014-07-21 | 2015-07-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3172227T1 true SI3172227T1 (sl) | 2020-02-28 |
Family
ID=55163946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530968T SI3172227T1 (sl) | 2014-07-21 | 2015-07-20 | Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni |
Country Status (22)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| PT3172227T (pt) * | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| SI3482766T1 (sl) | 2014-08-11 | 2020-09-30 | Delinia, Inc. | Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni |
| IL283764B2 (en) | 2015-04-10 | 2024-01-01 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| BR112018073606A2 (pt) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
| WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CA3041334A1 (en) | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| JP7228515B2 (ja) * | 2016-12-13 | 2023-02-24 | デリニア，インコーポレーテッド | 多価制御性ｔ細胞調節因子 |
| WO2018119114A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| CN110678550B (zh) * | 2017-03-29 | 2023-11-14 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| EP3713592A4 (en) | 2017-11-21 | 2022-01-12 | The Board of Trustees of the Leland Stanford Junior University | INTERLEUKIN-2 PARTIAL AGONISTS |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020005208A (es) * | 2017-12-06 | 2020-08-20 | Pandion Operations Inc | Muteinas de interleucina 2 (il-2) y usos de estas. |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CA3086842A1 (en) | 2017-12-27 | 2019-07-04 | Kyowa Kirin Co., Ltd. | Il-2 variant |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| EP3552738B1 (en) * | 2018-04-12 | 2024-07-31 | Sandvik Machining Solutions AB | A method of producing an additive manufactured object |
| CN120349426A (zh) | 2018-06-22 | 2025-07-22 | 科优基因公司 | 白介素-2变体及其使用方法 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| RU2021105821A (ru) | 2018-08-06 | 2021-05-27 | Медикайн, Инк. | Соединения, связывающие рецептор il-2 |
| ES3030707T3 (en) | 2018-08-13 | 2025-07-01 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| KR20210107714A (ko) * | 2018-12-21 | 2021-09-01 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 인간 인터류킨-2 변이체 또는 이의 유도체 |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| JP7570338B2 (ja) | 2019-02-15 | 2024-10-21 | インテグラル・モレキュラー・インコーポレイテッド | クローディン６抗体及びその使用 |
| WO2020168024A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| JP7483857B2 (ja) | 2019-07-26 | 2024-05-15 | ビステラ， インコーポレイテッド | インターロイキン－２作用物質およびその使用 |
| CA3148505A1 (en) * | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
| WO2021092075A1 (en) | 2019-11-05 | 2021-05-14 | Medikine Inc. | IL-2RβγC BINDING COMPOUNDS |
| BR112022008750A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
| AU2020401357A1 (en) * | 2019-12-12 | 2022-07-21 | Assistance Publique - Hôpitaux De Paris | Interleukin 2 chimeric constructs |
| IL293978A (en) * | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| WO2021158623A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | IL-7Rαγc BINDING COMPOUNDS |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| AU2021272895A1 (en) | 2020-05-12 | 2022-09-22 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス，インク． | タンパク質複合体の組成物及びその使用方法 |
| EP4208474A2 (en) * | 2020-09-01 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| MX2023004598A (es) | 2020-10-23 | 2023-06-29 | Asher Biotherapeutics Inc | Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias. |
| AU2021369823A1 (en) | 2020-10-29 | 2023-06-01 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| US20230398183A1 (en) | 2020-11-13 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
| KR20230129018A (ko) | 2020-12-04 | 2023-09-05 | 비스테라, 인크. | 인터류킨-2 작용제를 사용하는 방법 |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| US20220323607A1 (en) | 2021-04-09 | 2022-10-13 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| IL311883A (en) | 2021-10-06 | 2024-06-01 | Assist Publique H?Pitaux De Paris | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
| WO2023133319A1 (en) | 2022-01-10 | 2023-07-13 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| US20230372535A1 (en) | 2022-03-25 | 2023-11-23 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| CN115322260A (zh) * | 2022-06-13 | 2022-11-11 | 杭州高田生物医药有限公司 | 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用 |
| JP2025530309A (ja) | 2022-09-12 | 2025-09-11 | アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） | 自閉症スペクトラム障害の処置に使用するためのインターロイキン－２ |
| IL319951A (en) | 2022-11-30 | 2025-05-01 | Integral Molecular Inc | Antibodies targeting claudin 6, including its bispecific formats |
| KR20250133750A (ko) | 2023-01-09 | 2025-09-08 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-tnfr2 항원-결합 단백질 및 그의 용도 |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| ATE375388T1 (de) | 2001-07-27 | 2007-10-15 | Us Gov Health & Human Serv | Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| UA87458C2 (ru) | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| ES2383328T3 (es) * | 2003-07-25 | 2012-06-20 | Amgen, Inc | Métodos relacionados con LDCAM y CRTAM |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| AU2007271398B2 (en) | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| ME02371B (me) * | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| JP5766124B2 (ja) * | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| NZ594665A (en) * | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN102174111B (zh) * | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| HUE040326T2 (hu) * | 2011-02-10 | 2019-03-28 | Roche Glycart Ag | Mutáns interleukon-2 polipeptidek |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| DK2970486T3 (en) * | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| CN103193887B (zh) * | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| PT3172227T (pt) | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2015
- 2015-07-20 PT PT158249557T patent/PT3172227T/pt unknown
- 2015-07-20 RS RS20191448A patent/RS59789B1/sr unknown
- 2015-07-20 CN CN201580050979.6A patent/CN106795213B/zh not_active Expired - Fee Related
- 2015-07-20 EA EA202190903A patent/EA202190903A3/ru unknown
- 2015-07-20 SG SG10202010158TA patent/SG10202010158TA/en unknown
- 2015-07-20 DK DK15824955T patent/DK3172227T3/da active
- 2015-07-20 LT LTEP15824955.7T patent/LT3172227T/lt unknown
- 2015-07-20 CN CN202111371055.XA patent/CN114133456A/zh active Pending
- 2015-07-20 IL IL289475A patent/IL289475B2/en unknown
- 2015-07-20 SI SI201530968T patent/SI3172227T1/sl unknown
- 2015-07-20 WO PCT/US2015/041177 patent/WO2016014428A2/en not_active Ceased
- 2015-07-20 CA CA2954847A patent/CA2954847A1/en active Pending
- 2015-07-20 KR KR1020177001922A patent/KR102493543B1/ko active Active
- 2015-07-20 EP EP19188596.1A patent/EP3587444A1/en not_active Withdrawn
- 2015-07-20 JP JP2017504096A patent/JP6768633B2/ja not_active Expired - Fee Related
- 2015-07-20 ES ES15824955T patent/ES2763198T3/es active Active
- 2015-07-20 HU HUE15824955A patent/HUE046065T2/hu unknown
- 2015-07-20 MX MX2017000821A patent/MX378790B/es unknown
- 2015-07-20 EP EP15824955.7A patent/EP3172227B9/en active Active
- 2015-07-20 PL PL15824955T patent/PL3172227T3/pl unknown
- 2015-07-20 SG SG11201700514SA patent/SG11201700514SA/en unknown
- 2015-07-20 GB GB1615553.3A patent/GB2538666A/en not_active Withdrawn
- 2015-07-20 EA EA201790213A patent/EA038361B1/ru unknown
- 2015-07-20 AU AU2015292889A patent/AU2015292889C1/en not_active Withdrawn - After Issue
-
2016
- 2016-09-14 US US15/265,764 patent/US20170037102A1/en not_active Abandoned
- 2016-09-14 US US15/265,770 patent/US20170051029A1/en not_active Abandoned
-
2017
- 2017-01-10 IL IL250024A patent/IL250024B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00344A patent/ZA201700344B/en unknown
- 2017-01-18 MX MX2021000083A patent/MX2021000083A/es unknown
- 2017-07-28 US US15/662,633 patent/US20170327555A1/en not_active Abandoned
-
2019
- 2019-01-17 US US16/250,255 patent/US20190375812A1/en not_active Abandoned
-
2020
- 2020-04-07 US US16/841,815 patent/US20210047382A1/en not_active Abandoned
- 2020-05-27 AU AU2020203480A patent/AU2020203480A1/en not_active Abandoned
- 2020-09-02 JP JP2020147441A patent/JP2021006038A/ja active Pending
- 2020-10-26 IL IL278299A patent/IL278299B/en unknown
-
2021
- 2021-12-20 US US17/556,208 patent/US20220112260A1/en not_active Abandoned
-
2022
- 2022-07-11 AU AU2022204946A patent/AU2022204946A1/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289475A (en) | Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases | |
| ZA201804458B (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| ZA201700381B (en) | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201609770TA (en) | Combination therapies for the treatment of cancer | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| SI3122358T1 (sl) | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| IL249710A0 (en) | Wastewater treatment system | |
| PL3012014T3 (pl) | Instalacja obróbki płynu | |
| GB201411027D0 (en) | Treatment | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| ZA201403183B (en) | Effluent treatment system | |
| GB201412441D0 (en) | Treatment system | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment |